Victoria’s Secret and the Unraveling of an American icon, authors Lauren Sherman and Chantal Fernandez weave together the ...

GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 ...

Traders around the word awaited U.S. inflation data for September—and the implications it will have for rate cuts at the ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits ...

GSK shares jumped more than 5 per cent on Thursday after the pharma giant said it will pay up to £1.7billion to settle ...

The concerns surrounding Zantac also prompted UK health authorities to advise doctors in 2019 to cease prescribing specific formulations of the drug as a precautionary measure. Reports indicated that ...

The Financial Times top stories cover HSBC's targeted cost-cutting strategy focusing on senior bankers, the UK government's ...

The recent better-than-expected U.S. nonfarm payrolls data has many market participants on edge for a hotter-than-anticipated inflation reading, said Matt Simpson, market analyst at FOREX.com and City ...

The deal settles 80,000 US court cases related to allegations that Zantac was contaminated with a suspected carcinogen.

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...